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Abstract
Background: Optimisation of blood management in total hip (THA) and knee arthroplasty (TKA) is associated with
improved patient outcomes. This study aimed to establish the effectiveness of a perioperative blood management
programme in improving postoperative haemoglobin (Hb) and reducing the rate of allogenic blood transfusion.
Methods: This retrospective before and after study involves 200 consecutive patients undergoing elective TKA and
THA before (Usual Care group) and after (Intervention group) the introduction of a blood management programme in
an Australian teaching hospital. Patients in the Intervention group underwent preoperative treatment for anaemia and
received intraoperative tranexamic acid (15 mg/kg). The primary outcomeswere to compare postoperative Hb levels and
the rate of blood transfusion. Secondary outcomes includedmeasurements of total amount of allogenic blood transfused,
transfusion-related complications, postoperative complications, need for inpatient rehabilitation and duration of hospital stay.
Results: There were no differences between baseline characteristics between groups. Themean (SD) preoperative Hbwas
higher in the Intervention group compared to that in the Usual Care group: 138.7 (13.9) vs. 133.4 (13.9) g/L,
p= 0.008, respectively. The postoperative day 1 Hb, lowest postoperative Hb and discharge Hbwere all higher in the
Intervention group (p< 0.001). Blood transfusion requirements were lower in the Intervention group compared to the Usual
Care group (6 vs. 20%, p= 0.003). There were no differences in any of the secondary outcomesmeasured. Patients whowere
anaemic preoperatively andwho underwent Hb optimisation had higher Hb levels postoperatively (odds ratio 5.7; 95% CI 1.3
to 26.5; p= 0.024).
Conclusions: The introduction of a perioperative blood optimisation programme improved postoperative Hb levels and
reduced the rate of allogenic blood transfusion.
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Background
Surgery for total knee (TKA) and hip (THA) arthro-
plasty is common with a reported transfusion rate of ap-
proximately 26.8 % [1]. Eight to ten percent of all blood
transfusions in the UK are due to TKA and THA
surgery [2], and patients receiving blood from a
matched donor carry a risk of blood transfusion-related
complications [3, 4]. Furthermore, preoperative an-
aemia in elective TKA and THA is independently asso-
ciated with transfusion and increased postoperative
morbidity, supporting the need for preoperative evalu-
ation and treatment [5].
The National Blood Authority in Australia has released
a number of patient blood management initiatives recom-
mending the establishment of a multidisciplinary, multi-
modal perioperative blood management programme to
optimise preoperative red cell mass, minimise periopera-
tive blood loss and tolerate postoperative anaemia [6].
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Other blood management programmes are associated
with improved patient outcomes and reduced length of
stay [7]. In particular, it recommended that patients with
preoperative anaemia are identified, and if iron deficient,
preoperative iron therapy is advocated. [6]. Preoperative
iron supplementation is suggested for orthopaedic proce-
dures where there is a risk of severe postoperative anaemia
to reduce the need for transfusion [8]. Approximately
20 % of patients who present for joint reconstructive sur-
gery have coexisting anaemia, with 20 % of anaemic pa-
tients having anaemia responsive to iron therapy [9].
Intraoperative use of the anti-fibrinolytic tranexamic acid
has also been shown to effectively reduce transfusion rates
in TKR and THR without increasing the rate of other
complications, including thromboembolic events [10, 11].
The aim of this study was to evaluate the effectiveness
of the introduction of preoperative haemoglobin (Hb)
optimisation programme together with intraoperative
tranexamic acid to improve Hb levels postoperatively
and reduce the rate of blood transfusion in patients
undergoing primary elective THA and TKA.
Methods
Data from consecutive adult patients undergoing surgery
for primary elective TKA and THA in a university teach-
ing hospital were collected before (Usual Care group)
and after (Intervention group) the introduction of a Hb
optimisation programme that included the preoperative
optimisation and treatment of anaemia (men <130 g/L
and women <120 g/L) by a dedicated haematology clinic
and the intraoperative use of tranexamic acid (15 mg/kg
intravenously) (Fig. 1). This study is reported following
the STROBE statement checklist for observational stud-
ies [12].
Standard perioperative care for both groups included
strict transfusion practice in accordance with the Austra-
lian blood management perioperative guidelines [6]. In
the absence of ischaemic heart disease, a transfusion
trigger for blood transfusion was a Hb less than or equal
to 80 g/L. Adjuncts to minimise intraoperative blood
loss included the use of tourniquets in all total knee re-
placements. Haemostasis was achieved using diathermy
without the use of adjunct fibrin sealants. Continuous
passive motion and flexed knee approach in the first
hour in TKA patients was not used. Standard postopera-
tive care for all patients included a physical therapy-
based early mobilisation programme, commencing on
the day of surgery; multimodal analgesia led by a 24-h
acute pain service; and enoxaparin 40 mg subcutaneous
daily for venous thrombosis prophylaxis.
Exclusion criteria included patients with congenital or
acquired coagulopathy, congenital or acquired thrombo-
philia, history of thromboembolism, allergy to tranex-
amic acid and revision surgery. Patients were identified
using the Department of Orthopaedic audit database
and the hospital’s health information system. The pri-
mary aims were to determine if patients in the blood
management optimisation programme had higher Hb
levels immediately postoperatively and on hospital dis-
charge and if the rate of blood transfusion was lower
compared to the Usual Care group. Secondary aims in-
cluded measurements of total amount of allogenic blood
transfused, transfusion-related complications, postopera-
tive complications, need for inpatient rehabilitation and
duration of hospitals stay.
Other data collected included patient characteristics
including comorbidities, ASA status, preoperative inci-
dence of anaemia, preoperative renal function, preopera-
tive medications that impact on coagulation, surgical
approach, duration of surgery, type of anaesthetic and
amount of intravenous fluid administered. Postoperative
complications were identified from patients’ admission
histories, defined on the diagnoses written by the treat-
ing doctors in patients’ progress notes, with cross-
checking with laboratory and radiological data. The data
was collected by a principal investigator (PK) and with
the assistance of a research nurse.
At our institution, the proportion of patients prior to
the study that required a blood transfusion in the
Fig. 1 Overview of Usual Care and Intervention groups
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general orthopaedic setting was 25 %. A sample size cal-
culation of 194 subjects was based upon an 80 % chance
of detecting, as significant at the 5 % level, a decrease in
the primary outcome measure from 25 % transfusion
rate in the Usual Care group to 10 % in the Intervention
group. To allow for dropout and missing data, we col-
lected information from 200 patients. Results were sta-
tistically analysed using GraphPad (Prism 6®, Version
6.0b) with independent parametric data analysed with
unpaired t tests, non-parametric nominal data using chi-
square test and Mann-Whitney U test for independent
ordinal data. Backward multivariate regression modelling
was undertaken using SPSS (IBM SPSS Statistics for
Macintosh, Version 22.0) to examine for independent
factors associated with higher Hb levels in the postoper-
ative period and on hospital discharge. A p value of
<0.05 was considered statistically significant. The Austin
Health Research Ethics Committee granted prospective
ethics approval (HREC no H2013/04904).
Results
Data from 200 consecutive patients were collected be-
tween 2011 and 2013. Figure 2 outlines the numbers of
patients who were included and excluded in the study.
There were no differences between groups for baseline
patient characteristics, ASA status, comorbidities, or
preoperative medications relevant to bleeding (Table 1).
The preoperative biochemistry and haematological
results are presented in Table 2. There was no differ-
ence in coagulation profiles or renal function markers
between groups. In terms of operative data, there was
no difference between groups in the type of surgery,
surgical approaches or total number of surgeons per-
forming the operation. There was no significant dif-
ference in the number of patients who received a
surgical drain (Usual Care group 6 % vs. Intervention
group 4 %). The type of anaesthesia delivered did not
differ except for a reduction in femoral nerve blocks
inserted in the Intervention group. Intraoperatively,
the mean (SD) fluid intervention was 1862 (609) mL
vs. 2072 (736) mL in the Usual Care group, p = 0.029.
However, at 24 h, fluid intervention did not differ sig-
nificantly. The median (interquartile range (IQR))
duration of surgery was 120 (90:135) min in the
Intervention group vs. 120 (105:150) min in the Con-
trol group, p = 0.0254.
In the Usual Care group, iron studies were not part
of standard of care and no patient received preopera-
tive anaemia optimisation. Eighteen patients (18 %) in
the Usual Care group were anaemic preoperatively
(lowest Hb 88 g/L). Of the anaemic patients in the
Usual Care group, 9 (50 %) required a perioperative
blood transfusion. In the Intervention group during
screening preoperatively, 18 patients (18 %) were
anaemic or had low ferritin levels (<30 ng/mL) (low-
est Hb 100 g/L). Seven patients required iron supple-
mentation, five patients required dietary or cessation
of alcohol advice and six patients were optimised for
other causes of anaemia including anaemia of chronic
disease. No patients received erythropoietin. After the
Hb optimisation programme, seven patients (7 %)
remained anaemic preoperatively (lowest Hb 100 g/L),
with one of these patients requiring a perioperative
blood transfusion. Day 1 Hb, lowest postoperative Hb
and discharge Hb were all significantly higher in the
Intervention group (p < 0.001). These are summarised
graphically in Fig. 3.
Twenty patients (20 %) in the Usual Care group re-
quired a perioperative blood transfusion vs. six patients
(6 %) in the Intervention group (p = 0.003). The median
(IQR) number of units of blood transfused was 2 (1:2.75)
units in the Usual Care group and 2 (2:4.75) units in the
Intervention group (p = 0.126). The median (IQR) Hb
transfusion trigger was 76.0 (71: 82) g/L in the Usual Care
group vs. 74.0 (IQR 67: 87) g/L in the Intervention group
(p = 0.98). There were no differences between groups in
the length of hospital stay, need for inpatient rehabilita-
tion, complication rates or mortality (Table 3).
Preoperative anaemia alone was strongly associated with
the requirement for a perioperative blood transfusion
(odds ratio 6.1; 95 % CI 3.0 to 12.2). On multivariate re-
gression modelling, patients who were anaemic preopera-
tively and who underwent perioperative Hb optimisation
(i.e. preoperative treatment for anaemia plus intraopera-
tive tranexamic acid) had higher Hb levels immediately
postoperatively (odds ratio 5.7; 95 % CI 1.3 to 26.5; p =
0.024). A drop in Hb by 30 g/L or more on postoperative
day 1 (odds ratio 0.19; 95 % CI 0.05 to 0.99; p = 0.048) and
age greater than 65 years (odds ratio 0.19; 95 % CI 0.04 to
0.86; p = 0.031) were the only factors associated with Hb
less than 100 g/L on hospital discharge. Use of either tran-
examic acid alone or iron optimisation alone, ASA status,
duration of surgery, individual surgeons, intraoperative
fluid use, gender and BMI > 30 kg/m2 were not associated




We performed a retrospective quality assurance programme
evaluating the effectiveness of a change of practice of
preoperative treatment of anaemia utilising iron supple-
mentation together with intraoperative tranexamic acid
as recommended by National Blood Authority Patient
Blood Management Guidelines [6] to reduce the rate of
allogenic blood transfusion at our institution. We found
that the introduction of the blood optimisation
programme reduced the incidence of preoperative
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anaemia. In addition, patients undergoing elective THA
and TKA who underwent a perioperative blood man-
agement programme had a lower incidence of allogenic
blood transfusion. Patients who were anaemic pre-
operatively benefited most from the programme. This
has significant pharmacoeconomic and resource con-
siderations for institutions implementing similar blood
management strategies.
Relationship to previous studies
Previous studies have aimed to define an optimal strategy
for blood conservation in the setting of major orthopaedic
joint surgery. Kotze et al. performed a retrospective study
of 717 TKA and THA in the UK, analysing the effect of
instituting a blood management programme that included
the use of preoperative iron transfusions with erythropoi-
etin and intraoperative tranexamic acid with cell salvage
devices [2]. The programme significantly reduced the rate
of allogenic blood transfusion and length of stay. In our
study, we observed that there was no difference to length
of hospital stay between patients in the blood manage-
ment programme and the Usual Care groups. Similar
findings were reported by Wong et al. [13], who evaluated
the effectiveness of a comprehensive blood conservation
algorithm using a cluster randomisation trial design in-
volving 29 hospitals. Their programme consisted of spe-
cific blood conservation strategies including recombinant
human erythropoietin or autologous blood donation and
transfusion guidelines. Similar to our study, they demon-
strated that the comprehensive blood conservation was
superior to usual care for reducing allogenic transfusion,
despite no differences to length of hospital stay.
Our programme utilised treatment of preoperative
anaemia including use of iron supplementation and intra-
operative tranexamic acid. Previous studies in orthopaedic
procedures have demonstrated that preoperative iron
supplementation can reduce the need for transfusion, par-
ticularly in the context of expected postoperative anaemia
[8]. Approximately 20 % of patients who are anaemic at
presentation for joint reconstructive surgery will have an
anaemia that is responsive to iron therapy [8, 9]. On
regression modelling, we observed that patients who
appeared to benefit most from the programme were the
patients who were anaemic preoperatively and who
Fig. 2 Overview of total number of patients
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underwent the blood management programme. In the pa-
tients with preoperative anaemia who are also iron defi-
cient, iron loss due to surgical bleeding can exaggerate a
preexisting iron deficiency and may worsen postoperative
anaemia. Our findings of a drop in Hb by 30 g/L or more
on postoperative day 1 and age greater than 65 years were
negative, associated with Hb > 100 g/L on discharge; are
also physiologically plausible, i.e. the greater the intraoper-
ative blood loss, the lower the discharge Hb; and impaired
erythropoiesis in older patients [14].
Table 1 Baseline patient characteristics. Data presented as mean (standard deviation) or number and absolute percentages
Usual Care group Intervention group p
N = 100 N = 100
Sex; M:F 26:74 32:68 0.350
Age; years (SD, range) 68.1 (9.7, 46–94) 67.2 (10.9, 13–88) 0.547
Weight; kg (SD, range) 81.6 (17.8, 46–130) 83 (18.5, 50–137) 0.566
Body mass index; kg m−2 31.7 (6.4) 31.4 (6.7) 0.757
American Society Anesthesiology Status
1 4 3




Cardiac disease 18 17 0.852
Hypertension 65 62 0.660
Diabetes mellitus 22 16 0.280
Peripheral vascular disease 4 2 0.407
Cerebrovascular disease 6 1 0.054
Pulmonary embolus 1 0 0.316
Deep venous thrombosis 4 7 0.352
Renal impairment 5 11 0.118
Active smoker 10 5 0.180
Previous smoker 33 39 0.377
Chronic obstructive airways disease 20 21 0.861
Other 71 78 0.256
Preoperative medications
Aspirin 17 17 1.000
Clopidogrel 1 0 0.316
Warfarin 0 0 1.000
Non steroidal anti-inflammatory drugs 28 19 0.133
Table 2 Summary of preoperative biochemistry and haematology; data are presented as mean and standard deviation
Preoperative Usual Care group Intervention group p
N = 100 N = 100
Haemoglobin (g/L) 133.4 (13.9) 138.7 (13.9) 0.008
Mean corpuscular volume (fL) 89.9 (7.3) 88 (4.7) 0.032
Creatinine (μmol/L) 74.3 (20.4) 75 (19.5) 0.809
Estimated glomerular filtration rate (mL/min/1.73 m2) 79.8 (57.7) 76.8 (14.2) 0.621
Albumin (g/L) 41.1 (4.3) 40 (3.1) 0.036
Prothrombin time (s) 11.2 (1.8) 11 (1) 0.501
Activated partial thromboplastin time (s) 27.2 (4.7) 26.8 (4.1) 0.459
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Data from meta-analyses have previously supported
tranexamic acid in blood conservation in THA and TKA
without predisposing to thromboembolic complications
[10, 11]. In our study, similar to these studies, we ob-
served no complications relating to use of tranexamic
acid. Interestingly, we found that the use of tranexamic
acid was not an independent factor associated with im-
provements of Hb postoperatively. However, our study
aims were to evaluate the effectiveness of the introduc-
tion of preoperative Hb optimisation programme to-
gether with intraoperative tranexamic acid to improve
Hb levels postoperatively and reduce the rate of blood
transfusion. Inferences should therefore not be made
about the independent effectiveness of tranexamic acid
alone, as the study was not designed nor powered for
this purpose. The dosing strategy used in our study
(15 mg/kg) is considered a ‘low’ dose regime [10, 11],
and further research is still required to determine the
optimal dosing of tranexamic acid in the setting of major
arthroplasty surgery.
In addition to our study, we noted a significant reduc-
tion in the operative time in the Intervention group. Re-
ductions in operative times related to intraoperative
tranexamic acid use was not reported in three large
meta-analyses examining the use of tranexamic acid in
patients undergoing total hip and knee arthroplasty [10,
11, 15]. It is plausible that the use of tranexamic acid re-
duced time to achieve haemostasis, hence reducing the
duration of surgery. However, we consider an effect size
of 12 min for total duration of surgery to be of little clin-
ical significance. Future studies will need to validate this
finding with more robust study design for this particular
endpoint with consideration of its clinical and economic
importance.
Study implications
The clinical implications of our findings suggest that a
blood optimisation programme can safely and signifi-
cantly reduce the rate of allogenic blood transfusion in
accordance with recommendations by National Blood
Authority Patient Blood Management Guidelines [6]. In
addition, our findings provide support for the practice
change of deferral of surgery for investigation and treat-
ment of anaemia, with the combined used of tranexamic
acid for blood conservation. Importantly, as evident by
our findings, the use of tranexamic acid or iron opti-
misation alone were not associated with lower blood
transfusion requirements or higher Hb levels postopera-
tively, reinforcing the importance of multimodal blood
management strategies rather than single interventions.
Future studies could explore whether these measures
provide any pharmacoeconomic benefits to such an
intervention.
Strengths and limitations
There are several limitations to this quality assurance
retrospective before and after study. Firstly, the study de-
sign does not establish a causal relationship of the Hb
optimisation programme and the reduction in blood
transfusion or higher postoperative Hb levels observed
between the two groups. These associations may be sub-
ject to bias from selection, confounding or random error,
although we attempted to control for confounders by
using regression analysis. Specific biases regarding
Fig. 3 Postoperative haemoglobin values expressed as mean and standard deviation
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surgical decisions during the operation or the need for
blood transfusion cannot be excluded. However, the sur-
gical technique, surgeon and Hb transfusion triggers,
amongst the other variables outlined above, appeared to
be similar in both groups. Our findings only apply to
this type of surgery; therefore, they should not be
generalised to other orthopaedic or surgical procedures.
Furthermore, the external validity or generalisability of
our results to other hospitals is limited, since we col-
lected data only from a single institution. Although we
report a low incidence of deep vein thrombosis, which
was not different between the groups, we did not use
ultrasound to identify this complication, as in our insti-
tution this non-invasive imaging tool has been shown to
have a low sensitivity for detecting deep vein thrombosis.
Importantly, our institution does not routinely record
blood loss in the drains and was unable to accurately
quantify total blood loss. The dose of tranexamic acid
used in our programme may be different to other cen-
tres, and this may warrant further evaluation. We did
not perform any pharmacoeconomic evaluation of the
blood optimisation programme; however, this should not
detract from the study aims or objectives. Finally, the
intervention programme included a combination of both
preoperative haemoglobin optimisation and tranexamic
acid; the utility of the study is therefore limited in draw-
ing conclusions on each separate component of the
programme as eluded above.
Conclusions
The introduction of a preoperative blood optimisation
programme utilising iron supplementation combined
with intraoperative tranexamic acid has effectively re-
duced the use of allogenic blood transfusion in elective
total hip and knee arthroplasty surgeries at our institu-
tion. Patients who were anaemic preoperatively benefited
most from the programme. Our findings support the use
of a multidisciplinary blood optimisation programme in
this setting. These results can be used to build hypoth-
eses for further controlled trials.
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Table 3 Patient outcomes and complication rates. Data







N = 100 N = 100
Length of stay (h) 101.3 (98:128) 102.0 (84:125) 0.892
Discharge destination
Home 79 87 0.187
Inpatient rehabilitation 21 13
Complication rate
Total number of complications 16 17 0.849
Major complications 5 7 0.552
Acute coronary syndrome 3 0 0.081
Exacerbation of chronic lung
disease
0 1 0.316
Exacerbation of heart failure 0 1 0.316
Acute kidney injury 1 2 0.561
Pulmonary embolism 0 0 1.000
Narcotised from analgesia 1 3 0.312
Minor complication 11 10 0.818




Adverse drug reaction 1 0 0.316
Delirium 1 0 0.316
Deep vein thrombosis 0 0 1.000
Acute urinary retention 0 1 0.316
Uretheral injury 0 1 0.316





• Hypotension 7 5 0.390
• Oliguria 1 0 0.316
• Low respiratory rate 1 3 0.312
Cardiorespiratory arrest 0 0 1.000
Mortality 0 0 1.000
Intensive care admission 1 2 0.561
Readmission 2 0 0.155
• Wound cellulitis 1 0 0.316
• Hip dislocation 1 0 0.316
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